Collectively, our study suggests that the suppression of intestinal inflammation induced by bacterial elements through the LPS-activated TLR4/MyD88/NF-κB signaling pathway in the gut may play a critical role in the protective effects of FMT administration on PD. Here, MYD88 is linked to Parkinson disease.